M Stanley

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. ncbi HPV vaccines: where are we now?
    Margaret Stanley
    Department of Pathology, University of Cambridge, Cambridge, UK
    J Fam Plann Reprod Health Care 33:227-9. 2007
  2. ncbi Critical evaluation of HPV16 gene copy number quantification by SYBR green PCR
    Ian Roberts
    MRC Cancer Cell Unit, Hutchison MRC Research Centre, Hills Road, Cambridge, CB2 0XZ, UK
    BMC Biotechnol 8:57. 2008
  3. ncbi Potential mechanisms for HPV vaccine-induced long-term protection
    Margaret Stanley
    Department of Pathology, University of Cambridge, Cambridge, UK
    Gynecol Oncol 118:S2-7. 2010
  4. ncbi Human papillomavirus vaccines--immune responses
    Margaret Stanley
    Department of Pathology, Tennis Court Road, Cambridge, UK
    Vaccine 30:F83-7. 2012
  5. ncbi Genital human papillomavirus infections: current and prospective therapies
    Margaret A Stanley
    Department of Pathology, Tennis Court Road, Cambridge CB2 1QP, UK
    J Gen Virol 93:681-91. 2012
  6. ncbi Epithelial cell responses to infection with human papillomavirus
    Margaret A Stanley
    Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Clin Microbiol Rev 25:215-22. 2012
  7. ncbi HPV & head and neck cancer: a descriptive update
    Peter K C Goon
    Department of Pathology, University of Cambridge, Cambridge, UK
    Head Neck Oncol 1:36. 2009
  8. ncbi High prevalence of HPV in non-cervical sites of women with abnormal cervical cytology
    Robin Crawford
    Dept of Gynaecological Oncology, Addenbrooke s Hospital, Cambridge CB2 2QQ, UK
    BMC Cancer 11:473. 2011
  9. ncbi Sensitive HPV detection in oropharyngeal cancers
    David M Winder
    Dept of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK
    BMC Cancer 9:440. 2009
  10. ncbi Monitoring HPV vaccination
    Margaret Stanley
    Department of Pathology, Cambridge, UK
    Vaccine 26:A24-7. 2008

Collaborators

Detail Information

Publications35

  1. ncbi HPV vaccines: where are we now?
    Margaret Stanley
    Department of Pathology, University of Cambridge, Cambridge, UK
    J Fam Plann Reprod Health Care 33:227-9. 2007
  2. ncbi Critical evaluation of HPV16 gene copy number quantification by SYBR green PCR
    Ian Roberts
    MRC Cancer Cell Unit, Hutchison MRC Research Centre, Hills Road, Cambridge, CB2 0XZ, UK
    BMC Biotechnol 8:57. 2008
    ..We assessed a modified method, in which external calibration curves were generated from a single construct containing HPV16 E2, HPV16 E6 and the host gene hydroxymethylbilane synthase in a 1:1:1 ratio...
  3. ncbi Potential mechanisms for HPV vaccine-induced long-term protection
    Margaret Stanley
    Department of Pathology, University of Cambridge, Cambridge, UK
    Gynecol Oncol 118:S2-7. 2010
    ....
  4. ncbi Human papillomavirus vaccines--immune responses
    Margaret Stanley
    Department of Pathology, Tennis Court Road, Cambridge, UK
    Vaccine 30:F83-7. 2012
    ..This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012...
  5. ncbi Genital human papillomavirus infections: current and prospective therapies
    Margaret A Stanley
    Department of Pathology, Tennis Court Road, Cambridge CB2 1QP, UK
    J Gen Virol 93:681-91. 2012
    ..These studies are, however, at an early phase and it is unlikely that any specific anti-HPV chemotherapeutic will be in the clinic within the next 10-20 years...
  6. ncbi Epithelial cell responses to infection with human papillomavirus
    Margaret A Stanley
    Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Clin Microbiol Rev 25:215-22. 2012
    ..The wound exudate that results provides a mechanistic explanation for the protection offered by serum neutralizing antibody generated by HPV L1 virus-like particle (VLP) vaccines...
  7. ncbi HPV & head and neck cancer: a descriptive update
    Peter K C Goon
    Department of Pathology, University of Cambridge, Cambridge, UK
    Head Neck Oncol 1:36. 2009
    ..Finally, the improved prognosis and treatment responses to chemotherapy and radiotherapy by HPV+ tumours may suggest that HPV status detection is required to better plan and individualize patient treatment regimes...
  8. ncbi High prevalence of HPV in non-cervical sites of women with abnormal cervical cytology
    Robin Crawford
    Dept of Gynaecological Oncology, Addenbrooke s Hospital, Cambridge CB2 2QQ, UK
    BMC Cancer 11:473. 2011
    ....
  9. ncbi Sensitive HPV detection in oropharyngeal cancers
    David M Winder
    Dept of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK
    BMC Cancer 9:440. 2009
    ..To help ascertain a useful PCR detection protocol for oropharyngeal cancers, we directly compared three commonly used primer sets in detection of HPV from different clinical samples...
  10. ncbi Monitoring HPV vaccination
    Margaret Stanley
    Department of Pathology, Cambridge, UK
    Vaccine 26:A24-7. 2008
    ....
  11. ncbi HPV vaccines: are they the answer?
    Margaret Stanley
    Department of Pathology, Tennis Court Road, Cambridge CB21QP, UK
    Br Med Bull 88:59-74. 2008
    ....
  12. ncbi Prospects for new human papillomavirus vaccines
    Margaret Stanley
    Department of Pathology, University of Cambridge, Cambridge, UK
    Curr Opin Infect Dis 23:70-5. 2010
    ..However, these vaccines, at the present, protect against only two of the 15 oncogenic genital HPV types, they are expensive, delivered by intramuscular injection and require a cold chain...
  13. ncbi Chapter 12: Prophylactic HPV vaccines: underlying mechanisms
    Margaret Stanley
    Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, UK
    Vaccine 24:S3/106-13. 2006
    ..Important issues remaining to be addressed include the duration of protection and genotype replacement...
  14. ncbi Prophylactic human papillomavirus vaccines: will they do their job?
    M Stanley
    Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK
    J Intern Med 267:251-9. 2010
    ....
  15. ncbi Pathology and epidemiology of HPV infection in females
    Margaret Stanley
    Department of Pathology, University of Cambridge, UK
    Gynecol Oncol 117:S5-10. 2010
    ..HPV DNA testing has been shown consistently to be superior to cytology in terms of sensitivity and positive predictive value and will become a major tool in cervical cancer screening, at least in the developed countries...
  16. ncbi HPV - immune response to infection and vaccination
    Margaret Stanley
    Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK
    Infect Agent Cancer 5:19. 2010
    ..Recent data on how HPV infects basal epithelial cells and how antibody can prevent this provides a mechanistic explanation for the effectiveness of HPV VLP vaccines...
  17. ncbi Immunobiology of HPV and HPV vaccines
    Margaret Stanley
    Department of Pathology, Tennis Court Road, University of Cambridge, CB2 1QP UK
    Gynecol Oncol 109:S15-21. 2008
    ....
  18. ncbi Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis
    Y L Woo
    Department of Pathology, University of Cambridge, Cambridge, UK
    BJOG 115:1616-21; discussion 1621-2. 2008
    ..Information on the local immunological changes during the natural course of CIN is central for the development of new therapies...
  19. ncbi Human papillomavirus vaccines versus cervical cancer screening
    M Stanley
    Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, UK
    Clin Oncol (R Coll Radiol) 20:388-94. 2008
    ..However, if both vaccination and screening are combined then the virtual elimination of cervical cancer and the other HPV 16 and 18-associated cancers is possible...
  20. ncbi Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer
    M Stanley
    Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK
    Br J Cancer 96:1320-3. 2007
    ....
  21. ncbi Immune responses to human papillomavirus
    Margaret Stanley
    University of Cambridge, Department of Pathology, Tennis Court Road, Cambridge CB2 1QP, UK
    Vaccine 24:S16-22. 2006
    ..Available data suggests that these vaccines are safe, produce high levels of antibodies, and are effective at preventing HPV infection...
  22. ncbi HPV vaccines
    Margaret Stanley
    Department of Pathology, Tennis Court Road, Cambridge CB2 1QP, UK
    Best Pract Res Clin Obstet Gynaecol 20:279-93. 2006
    ..Therapeutic vaccines for low-grade intraepithelial disease are realistic but high-grade disease presents major hurdles for immunotherapies...
  23. ncbi The use of HPV Linear Array Assay for multiple HPV typing on archival frozen tissue and DNA specimens
    Yin Ling Woo
    Division of Virology, Department of Pathology, University of Cambridge, CB2 2QQ Cambridge, UK
    J Virol Methods 142:226-30. 2007
    ..The utility of this kit for multiple HPV typing of archival frozen tissue and cervical cells not collected in PreservCyt are described...
  24. ncbi Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines
    Margaret Stanley
    Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Vaccine 26:K62-7. 2008
    ..This will be central in the development of adjuvants and vaccine formulations that induce the response to provide effective protection...
  25. ncbi Prophylactic HPV vaccines
    Margaret Stanley
    Department of Pathology, University of Cambridge, Cambridge, UK
    Drugs Today (Barc) 43:737-44. 2007
    ..The health economic benefits will be substantial but the overwhelming benefit is the major improvement for human health and well-being. (..
  26. ncbi Expression of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, renaturation, and self-assembly of virus-like particles in vitro
    W Zhang
    Department of Pathology, University of Cambridge, United Kingdom
    Virology 243:423-31. 1998
    ..This system offers not only a model for investigation of the intrinsic interactions that occur during L1 assembly, but also a potential route for convenient manufacture of highly purified VLP vaccines...
  27. ncbi Immune intervention in HPV infections: current progress and future developments
    Margaret Stanley
    Department of Pathology, Tennis Court Road, Cambridge CB2 1QP, UK
    Expert Rev Vaccines 2:615-7. 2003
  28. ncbi The interaction between human papillomavirus type 16 E1 and E2 proteins is blocked by an antibody to the N-terminal region of E2
    M H Hibma
    Imperial Cancer Research Fund Tumor Virus Group, Department of Pathology, University of Cambridge, England
    Eur J Biochem 229:517-25. 1995
    ..These results suggest that a region in the N-terminus of E2 around amino acids 18-41 is a site of interaction with the E1 protein...
  29. ncbi Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus
    C S McLean
    Department of Pathology, University of Cambridge
    J Clin Pathol 43:488-92. 1990
    ..This greatly increases the probability that an identified antibody will be useful in a clinical setting...
  30. ncbi FOXP3 immunohistochemistry on formalin-fixed paraffin-embedded tissue: poor correlation between different antibodies
    Y L Woo
    Department of Pathology, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    J Clin Pathol 61:969-71. 2008
    ..The antibodies targeting different FOXP3 epitopes unexpectedly resulted in significantly different staining patterns. This phenomenon has not been previously reported and is likely to be an important observation...
  31. ncbi Prevention strategies against the human papillomavirus: the effectiveness of vaccination
    M Stanley
    Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK
    Gynecol Oncol 107:S19-23. 2007
    ..Predictive data also indicate that the implementation of HPV vaccination within a national screening program is likely to be cost-effective relative to current clinical practice...
  32. ncbi The epidemiology and burden of HPV disease
    Margaret Stanley
    Department of Pathology, University of Cambridge, Cambridge
    Nurs Times 104:38-40. 2008
    ..Margaret Stanley describes what human papillomavirus is and how it causes disease. She also outlines how the new vaccine to protect against HPV works...
  33. ncbi The end for genital human papillomavirus infections?
    Margaret Stanley
    Lancet Oncol 6:256-7. 2005
  34. ncbi Antibody reactivity to HPV E6 and E7 oncoproteins and early diagnosis of invasive cervical cancer
    Margaret Stanley
    Am J Obstet Gynecol 188:3-4. 2003
  35. ncbi Prophylactic HPV vaccines
    Margaret Stanley
    J Clin Pathol 60:961-5. 2007